Residency · Residency · Internal Medicine

Type 2 Diabetes: Individualized Pharmacotherapy Beyond Metformin

Introduction

The management of type 2 diabetes has undergone a paradigm shift. While metformin remains a reasonable first-line agent, the 2022 ADA/EASD consensus and subsequent updates emphasize a cardiorenal-metabolic approach where agent selection is driven by comorbidities rather than glucose lowering alone. The emergence of GLP-1 receptor agonists and SGLT2 inhibitors with proven cardiovascular and renal benefits has fundamentally changed the treatment algorithm.

Glycemic Targets

• HbA1c < 7% for most non-pregnant adults (ADA standard target)
• HbA1c < 6.5% if achievable without significant hypoglycemia (select younger patients, short disease duration)
• HbA1c < 8% for elderly patients, limited life expectancy, extensive comorbidities, or high hypoglycemia risk
• Time in range (TIR): > 70% of time between 70-180 mg/dL on continuous glucose monitoring correlates with HbA1c < 7%

Metformin: The Traditional Foundation

• Mechanism: reduces hepatic glucose production, improves insulin sensitivity
• Benefits: low cost, weight neutral to modest weight loss, no hypoglycemia, extensive safety record
• Limitations: GI side effects (use extended-release to mitigate), contraindicated if eGFR < 30 mL/min, dose reduction at eGFR < 45
• Key shift: ADA 2023 guidelines state that SGLT2i or GLP-1 RA should be initiated for cardiorenal benefit independent of HbA1c and independent of metformin use

SGLT2 Inhibitors

Agents and Mechanism

• Empagliflozin, dapagliflozin, canagliflozin, ertugliflozin
• Block sodium-glucose cotransporter 2 in the proximal tubule, causing glycosuria
• HbA1c reduction: 0.5-0.8%
• Weight loss: 2-3 kg; systolic BP reduction: 3-5 mmHg

Cardiovascular and Renal Benefits

• EMPA-REG OUTCOME: empagliflozin reduced cardiovascular death by 38% and heart failure hospitalization by 35%
• DAPA-HF / EMPEROR-Reduced: benefit in HFrEF regardless of diabetes status
• CREDENCE / DAPA-CKD: slowed CKD progression, reduced albuminuria
• Indications beyond glucose: HFrEF, HFpEF, CKD with albuminuria (now used in non-diabetic populations)

Adverse Effects and Precautions

• Genital mycotic infections (most common, 5-10%)
• Euglycemic diabetic ketoacidosis: rare; hold peri-operatively and during acute illness
• Volume depletion: caution in elderly, diuretic use
• Canagliflozin: historical signal for amputations and fractures (not confirmed with other agents)

GLP-1 Receptor Agonists

Agents and Mechanism

• Semaglutide (subcutaneous weekly, oral daily), liraglutide (daily), dulaglutide (weekly), tirzepatide (dual GIP/GLP-1 agonist, weekly)
• Enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, promote satiety
• HbA1c reduction: 1.0-2.0%; weight loss: 5-15% (tirzepatide up to 20%)

Landmark Trials

• SUSTAIN-6 / PIONEER-6: semaglutide reduced MACE
• LEADER: liraglutide reduced cardiovascular death by 22%
• SURPASS trials: tirzepatide achieved HbA1c < 5.7% in up to 50% of participants
• SELECT: semaglutide 2.4 mg reduced MACE by 20% in patients with obesity and established CVD without diabetes

Adverse Effects

• GI symptoms (nausea, vomiting, diarrhea): dose-escalate gradually to mitigate
• Pancreatitis: rare; avoid in patients with prior pancreatitis
• Thyroid C-cell tumors: signal in rodents; contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
• Gallbladder disease: increased risk with rapid weight loss

Other Agents

DPP-4 Inhibitors

• Sitagliptin, linagliptin, saxagliptin, alogliptin
• Modest HbA1c reduction (0.5-0.7%), weight neutral, well-tolerated
• Cardiovascular safety trials showed neutrality (no benefit, no harm, except saxagliptin and HF risk)
• Role diminishing as GLP-1 RAs become more accessible

Thiazolidinediones

• Pioglitazone: improves insulin sensitivity, durable glucose lowering, NASH benefit (histologic improvement)
• Risks: weight gain, fluid retention, heart failure exacerbation, fractures, bladder cancer concern
• Consider in NASH with insulin resistance if no contraindications

Insulin

• Basal insulin (glargine, degludec): add when oral/injectable agents fail to achieve target
• Basal-bolus or premixed regimens: for advanced disease with significant beta-cell failure
• Degludec has lower hypoglycemia risk than glargine U100 (DEVOTE trial)
• Insulin + GLP-1 RA fixed-ratio combinations (iDegLira, iGlarLixi): simplify regimens, mitigate insulin-associated weight gain

The Modern Treatment Algorithm

1. Assess for ASCVD, heart failure, or CKD at diagnosis
2. If ASCVD or high CV risk: GLP-1 RA with proven benefit (semaglutide, liraglutide, dulaglutide)
3. If HF: SGLT2 inhibitor (empagliflozin, dapagliflozin)
4. If CKD with albuminuria: SGLT2 inhibitor (independent of glucose); consider adding finerenone (non-steroidal MRA)
5. If primary goal is weight management: tirzepatide or semaglutide
6. If cost is a major barrier: metformin + sulfonylurea or pioglitazone
7. Reassess HbA1c every 3 months; intensify therapy if above target

Key Clinical Pearls

• SGLT2 inhibitors and GLP-1 RAs should be prescribed for their cardiorenal benefits independent of HbA1c level
• Tirzepatide (dual GIP/GLP-1 agonist) produces the greatest HbA1c reduction and weight loss of any non-insulin agent
• Hold SGLT2 inhibitors 3-4 days before planned surgery to prevent euglycemic DKA
• Never combine a GLP-1 RA with a DPP-4 inhibitor (redundant mechanism; no added benefit)

References

1. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022: A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786.
2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
4. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436-1446.

For the intern

At 3am, you'll be asked to address acute issues—severe hyperglycemia (glucose >400 mg/dL), suspected euglycemic diabetic ketoacidosis (DKA) in a patient on SGLT2 inhibitor, or hypoglycemia. Check fingerstick glucose, basic metabolic panel, and beta-hydroxybutyrate if altered mental status exists. Hold SGLT2 inhibitors during acute illness or before surgery. Start insulin if glucose remains critically elevated despite fluids. Everything else—initiating glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, adjusting outpatient regimens, or counseling on weight loss—waits for morning rounds when you can review comorbidities and individualize the plan based on cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) status.

Common pitfalls

• Forgetting cardiorenal indications: SGLT2 inhibitors and GLP-1 RAs aren't just glucose drugs. If your patient has established atherosclerotic CVD, HF, or albuminuric CKD, these agents should be prescribed regardless of HbA1c control.
• Combining GLP-1 RA with DPP-4 inhibitor: They share overlapping mechanisms (incretin pathway). This combination offers no additional benefit and wastes money. Stop the DPP-4 inhibitor when starting a GLP-1 RA.
• Continuing SGLT2 inhibitors peri-operatively: Hold empagliflozin, dapagliflozin, or canagliflozin 3–4 days before planned surgery to prevent euglycemic DKA, a rare but dangerous complication.
• Ignoring volume status: SGLT2 inhibitors cause osmotic diuresis. In elderly patients already on loop diuretics, watch for orthostatic hypotension and acute kidney injury from intravascular depletion.

Make it stick (one 80-word vignette)

A 68-year-old male presents for follow-up of type 2 diabetes. He has a history of coronary artery disease with prior myocardial infarction and chronic kidney disease stage 3. His current medications include metformin and sitagliptin. His HbA1c is 7.2%. Despite good glycemic control, based on the principle of individualized pharmacotherapy, his regimen needs optimization to provide cardiorenal protection. An SGLT2 inhibitor should be added for his heart failure and CKD, and a GLP-1 receptor agonist for his atherosclerotic cardiovascular disease, replacing sitagliptin.

If you remember one thing

Individualized pharmacotherapy for type 2 diabetes prioritizes cardiorenal protection; therefore, SGLT2 inhibitors and GLP-1 receptor agonists are first-line agents in patients with established cardiovascular disease, heart failure, or chronic kidney disease, regardless of initial glycemic control. Never combine a GLP-1 receptor agonist with a DPP-4 inhibitor, and always hold SGLT2 inhibitors peri-operatively to prevent euglycemic DKA.

Read this lecture as Markdown